Puma Biotechnology, Inc. (NasdaqGS: PBYI)
Health Care · Biotechnology · US
$9.97
+1.63% today · +89.4% 1Y
Puma Biotechnology, Inc. (NasdaqGS: PBYI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $506.39M and employs 179 people.
Over the last twelve months the share price has gained 89.4%, trading between 4.58 and 10.10.
Tweenvest scores Puma Biotechnology, Inc. across four factors: quality 74/100, value 18/100, growth 0/100. Its strongest factor is quality.
PBYI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $506.39M
- Revenue (TTM)
- $231.24M
- P/E
- 19.48
- EPS
- 0.50
- Dividend yield
- —
- Beta (5Y)
- 1.21
- 52-week high
- $10.10
- 52-week low
- $4.58
- Avg volume (3M)
- —
- Shares outstanding
- 51.62M
- Employees
- 179
- Next earnings
- —
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
- ISIN
- US74587V1070
- Founded
- 2010
- Listed since
- Apr 24, 2012
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Altimmune, Inc.NasdaqGM: ALT | $517.42M | $2.60 | -2.26% |
| Lifecome Biochemistry Co.,Ltd.SZSE: 002868 | $516.68M | CN¥22.30 | -0.54% |
| Genfit S.A.ENXTPA: GNFT | $512.35M | €8.33 | -8.46% |
| Ever Supreme Bio Technology Co., LtdTPEX: 6712 | $509.11M | NT$161.00 | +0.94% |
| REGENXBIO Inc.NasdaqGS: RGNX | $501.37M | $8.09 | +6.52% |
| Gongwin Biopharm Holdings Co., Ltd.TPEX: 6617 | $499.99M | NT$131.50 | -4.01% |
| Wuhan Hiteck Biological Pharma Co.,LtdSZSE: 300683 | $498.38M | CN¥25.54 | +1.51% |
| Shanghai Bao Pharmaceuticals Co., Ltd.SEHK: 2659 | $497.68M | HK$12.08 | -4.88% |
Figures last refreshed Oct 4, 2026.